Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez Santos, Paula
  • Baldán Martín, Montserrat
  • López, Juan A.
  • Martín Lorenzo, Marta
  • Santiago Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera Sierra, Martha
  • Calvo, Eva
  • Vázquez, Jesús
  • Ruiz Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope Urioste, Luis Miguel
  • Barderas, María G.
  • Álvarez Llamas, Gloria
Background and aims The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. Methods: Eighty-one subjects (30–50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients’ cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. Results: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. Conclusions: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
Docta Complutense
Publication Artículo científico (JournalArticle)

Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension

  • Martín Lorenzo, Marta
  • Martínez, Paula J.
  • Baldán Martín, Montserrat
  • López, Juan A.
  • Mínguez, Pablo
  • Santiago Hernández, Aránzazu
  • Vázquez, Jesús
  • Segura, Julián
  • Ruiz Hurtado, Gema
  • Vivanco, Fernando
  • Barderas, María G.
  • Ruilope Urioste, Luis Miguel
  • Álvarez Llamas, Gloria
Resistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient’s response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography–mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients’ response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients’ management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.
Repisalud
Publication Artículo científico (JournalArticle)

Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers

  • Tapial, Sandra
  • Olmedillas-López, Susana
  • Rueda, Daniel
  • Arriba, María
  • García, Juan L
  • Vivas, Alfredo
  • Pérez, Jessica
  • Pena-Couso, Laura
  • Olivera, Rocío
  • Rodríguez, Yolanda
  • García-Arranz, Mariano
  • García-Olmo, Damián
  • González-Sarmiento, Rogelio
  • Urioste, Miguel
  • Goel, Ajay
  • Perea, José
Colorectal cancer (CRC) with CpG island methylator phenotype (CIMP) is recognized as a subgroup of CRC that shows association with particular genetic defects and patient outcomes. We analyzed CIMP status of 229 individuals with CRC using an eight-marker panel (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); CIMP-(+) tumors were defined as having ≥ 5 methylated markers. Patients were divided into individuals who developed a "unique" CRC, which were subclassified into early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and patients with multiple primary CRCs subclassified into synchronous CRC (SCRC) and metachronous CRC (MCRC). We found 9 (15.2%) CIMP-(+) EOCRC patients related with the proximal colon (p = 0.008), and 19 (26.8%) CIMP-(+) LOCRC patients associated with tumor differentiation (p = 0.045), MSI status (p = 0.021) and BRAF mutation (p = 0.001). Thirty-five (64.8%) SCRC patients had at least one CIMP-(+) tumor and 20 (44.4%) MCRC patients presented their first tumor as CIMP-(+). Thirty-nine (72.2%) SCRC patients showed concordant CIMP status in their simultaneous tumors. The differences in CIMP-(+) frequency between groups may reflect the importance of taking into account several criteria for the development of multiple primary neoplasms. Additionally, the concordance between synchronous tumors suggests CIMP status is generally maintained in SCRC patients.
Repisalud
Publication Artículo científico (JournalArticle)

Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer

  • Álvaro, Edurne
  • Cano, Juana M
  • García, Juan L
  • Brandáriz, Lorena
  • Olmedillas-López, Susana
  • Arriba, María
  • Rueda, Daniel
  • Rodríguez, Yolanda
  • Cañete, Ángel
  • Arribas, Julia
  • Inglada Perez, Lucia
  • Pérez, Jessica
  • Gómez, Carlos
  • García-Arranz, Mariano
  • García-Olmo, Damián
  • Goel, Ajay
  • Urioste, Miguel
  • González-Sarmiento, Rogelio
  • Perea, José
Our aim was to characterize and validate that the location and age of onset of the tumor are both important criteria to classify colorectal cancer (CRC). We analyzed clinical and molecular characteristics of early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and we compared each tumor location between both ages-of-onset. In right-sided colon tumors, early-onset cases showed extensive Lynch syndrome (LS) features, with a relatively low frequency of chromosomal instability (CIN), but a high CpG island methylation phenotype. Nevertheless, late-onset cases showed predominantly sporadic features and microsatellite instability cases due to BRAF mutations. In left colon cancers, the most reliable clinical features were the tendency to develop polyps as well as multiple primary CRC associated with the late-onset subset. Apart from the higher degree of CIN in left-sided early-onset cancers, differential copy number alterations were also observed. Differences among rectal cancers showed that early-onset rectal cancers were diagnosed at later stages, had less association with polyps, and more than half of them were associated with a familial LS component. Stratifying CRC according to both location and age-of-onset criteria is meaningful, not only because it correlates the resulting categories with certain molecular bases, but with the confirmation across larger studies, new therapeutical algorithms could be defined according to this subclassification.
Repisalud
Publication Artículo científico (JournalArticle)

Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer

  • Arriba, María
  • Sánchez, Carmen
  • Vivas, Alfredo
  • Nutu, O A
  • Rueda, Daniel
  • Tapial, Sandra
  • Rodríguez, Yolanda
  • Brandáriz, Lorena
  • García, Juan L
  • García-Olmo, Damián
  • Goel, Ajay
  • González-Sarmiento, Rogelio
  • Urioste, Miguel
  • Perea, José
Comparative studies of colorectal cancer (CRC) according to the age of onset have found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC). Using this as a starting point, we wished to determine whether intermediate-onset CRC (IOCRC) might also be considered as an independent group within CRC. We performed a retrospective comparative study of the clinicopathological and familial features, as well as of the symptoms and their duration, of a total of 272 subjects diagnosed with CRC classified into three groups according to the age-of-onset (98 EOCRC, 83 IOCRC and 91 LOCRC). The results show that from a clinicopathological point of view, IOCRC shared certain features with EOCRC (gender, prognosis), and with LOCRC (multiple primary CRCs), whereas it also had characteristics that were specific for IOCRC (mean number of associated polyps). A gradual progression was observed from EOCRC to LOCRC from a greater family aggregation to sporadic cases, in parallel with a change of Lynch Syndrome cases to the sporadic microsatellite instability pathway, with the IOCRC being a boundary group that is more related to EOCRC. With respect to symptoms, duration and correlation with stages, IOCRC appeared more similar to EOCRC. Clinically, IOCRC behaves as a transitional group between EOCRC and LOCRC, with features in common with both groups, but also with IOCRC-specific features. Excluding cases with familial cancer history, the awareness for EOCRC diagnosis should be extended to IOCRC.
Repisalud
Publication Artículo científico (JournalArticle)

Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria

  • de la Cuesta, Fernando
  • Baldan-Martin, Montserrat
  • Moreno-Luna, Rafael
  • Alvarez-Llamas, Gloria
  • Gonzalez-Calero, Laura
  • Mourino-Alvarez, Laura
  • Sastre-Oliva, Tamara
  • Lopez, Juan Antonio
  • Vazquez, Jesus
  • Ruiz-Hurtado, Gema
  • Segura, Julian
  • Vivanco, Fernando
  • Ruilope, Luis M
  • Barderas, Maria G
Despite of the great advances in anti-hypertensive therapies, many patients under Renin-Angiotensin-System (RAS) suppression develop albuminuria, which is a clear indicator of therapeutic inefficiency. Hence, indicators of vascular function are needed to assess patients' condition and help deciding future therapies. Proteomic analysis of circulating extracellular vesicles (EVs) showed two proteins, kalirin and chromodomain-helicase-DNA-binding protein 7 (CHD7), increased in albuminuric patients. A positive correlation of both with the expression of the endothelial activation marker E-selectin was found in EVs. In vitro analysis using TNFa-treated adult human endothelial cells proved their involvement in endothelial cell activation. Hence, we propose protein levels of kalirin and CHD7 in circulating EVs as novel endothelial dysfunction markers to monitor vascular condition in hypertensive patients with albuminuria.
Repisalud
Publication Artículo científico (JournalArticle)

Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators

  • Baldan-Martin, Montserrat
  • Mourino-Alvarez, Laura
  • Gonzalez-Calero, Laura
  • Moreno-Luna, Rafael
  • Sastre-Oliva, Tamara
  • Ruiz-Hurtado, Gema
  • Segura, Julian
  • Lopez, Juan Antonio
  • Vazquez, Jesus
  • Vivanco, Fernando
  • Alvarez-Llamas, Gloria
  • Ruilope, Luis M
  • de la Cuesta, Fernando
  • Barderas, Maria G
Albuminuria is a risk factor strongly associated with cardiovascular disease, the first cause of death in the general population. It is well established that renin-angiotensin system suppressors prevent the development of new-onset albuminuria in naïf hypertensive patients and diminish its excretion, but we cannot forget the percentage of hypertensive patients who develop de novo albuminuria. Here, we applied multiple proteomic strategy with the purpose to elucidate specific molecular pathways involved in the pathogenesis and provide predictors and chronic organ damage indicators. Briefly, 1143 patients were followed up for a minimum period of 3 years. One hundred and twenty-nine hypertensive patients chronically renin-angiotensin system suppressed were recruited, classified in 3 different groups depending on their albuminuria levels (normoalbuminuria, de novo albuminuria, and sustained albuminuria), and investigated by multiple proteomic strategies. Our strategy allowed us to perform one of the deepest plasma proteomic analysis to date, which has shown 2 proteomic signatures: (1) with predictive value of de novo albuminuria and (2) sustained albuminuria indicator proteins. These proteins are involved in inflammation, immune as well as in the proteasome activation occurring in situations of endoplasmic reticulum stress. Furthermore, these results open the possibility of a future strategy based on anti-immune therapy to treat hypertension which could help to prevent the development of albuminuria and, hence, the progression of kidney damage.
Repisalud
Publication Artículo científico (JournalArticle)

Redefining synchronous colorectal cancers based on tumor clonality

  • Perea, José
  • García, Juan L
  • Corchete, Luis
  • Lumbreras, Eva
  • Arriba, María
  • Rueda, Daniel
  • Tapial, Sandra
  • Pérez, Jessica
  • Vieiro, Victoria
  • Rodríguez, Yolanda
  • Brandáriz, Lorena
  • García-Arranz, Mariano
  • García-Olmo, Damián
  • Goel, Ajay
  • Urioste, Miguel
  • González-Sarmiento, Rogelio
To analyze the possible clonal origin of a part of Synchronous colorectal cancer (SCRC), we studied 104 paired-SCRCs from 52 consecutive patients without hereditary forms of CRC. We used a Single-Nucleotide Polymorphism array to characterize the genomic profiles, and subsequently used a statistical application to define them according to clonality within the same individual. We categorized the ensuing groups according to colonic location to identify differential phenotypes. The SCRC Monoclonal group (M) (19 cases) was divided into Monosegmental (MM) and Pancolonic (MP) groups. The SCRC Polyclonal group (P) (33 cases) was also divided into Monosegmental (PM) and Pancolonic (PP), the first exhibiting preference for left colon. The MM group showed a high rate of mucinous tumors, the lowest mean-number of tumors and associated-polyps, and the worst prognosis. The MP group included the largest mean-number of associated-polyps, best prognosis and familial cancer component. The PM group seemed to be a "frontier" group. Finally, the PP group also exhibited a mucin component, the highest mean-number of tumors (4.6) compared with the mean-number of polyps (7.7), poor prognosis and sporadic cases. Most relevant differential genomic regions within M groups were gains on 1q24 and 8q24, and deletions on 1p21 and 1p23 for MM, while within P were the gains on 7q36 and deletions on 1p36 for PM. The statistical application employed seems to define clonality more accurately in SCRC -more likely to be polyclonal in origin-, and together with the tumor locations, helped us to configure a classification with prognostic and clinical value.
Repisalud
Publication Artículo científico (JournalArticle)

Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension

  • Martin-Lorenzo, Marta
  • Martinez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Minguez, Pablo
  • Santiago-Hernandez, Aranzazu
  • Vazquez, Jesus
  • Segura, Julian
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Barderas, Maria G
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Resistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient's response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography-mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients' response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients' management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.
Repisalud
Publication Artículo científico (JournalArticle)

Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria

  • Martin-Lorenzo, Marta
  • Gonzalez-Calero, Laura
  • Martinez, Paula J.
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Ruiz-Hurtado, Gema
  • de la Cuesta, Fernando
  • Segura, Julian
  • Vazquez, Jesus
  • Vivanco, Fernando
  • Barderas, Maria G
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Albuminuria development in hypertensive patients is an indicator of higher cardiovascular (CV) risk and renal damage. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control but it does not prevent from albuminuria development. We pursued the identification of protein indicators in urine behind albuminuria development in hypertensive patients under RAS suppression. Urine was collected from 100 patients classified in three groups according to albuminuria development: (a) patients with persistent normoalbuminuria; (b) patients developing de novo albuminuria; (c) patients with maintained albuminuria. Quantitative analysis was performed in a first discovery cohort by isobaric labeling methodology. Alterations of proteins of interest were confirmed by target mass spectrometry analysis in an independent cohort. A total of 2416 proteins and 1223 functional categories (coordinated protein responses) were identified. Immune response, adhesion of immune and blood cells, and phagocytosis were found significantly altered in patients with albuminuria compared to normoalbuminuric individuals. The complement system C3 increases, while Annexin A1, CD44, S100A8 and S100A9 proteins showed significant diminishment in their urinary levels when albuminuria is present. This study reveals specific links between immune response and controlled hypertension in patients who develop albuminuria, pointing to potential protein targets for novel and future therapeutic interventions.
Repisalud
Publication Artículo científico (JournalArticle)

Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria

  • Gonzalez-Calero, Laura
  • Martinez, Paula J.
  • Martin-Lorenzo, Marta
  • Baldan-Martin, Montserrat
  • Ruiz-Hurtado, Gema
  • de la Cuesta, Fernando
  • Calvo, Eva
  • Segura, Julian
  • Lopez, Juan Antonio
  • Vazquez, Jesus
  • Barderas, Maria G
  • Ruilope, Luis M
  • Vivanco, Fernando
  • Alvarez-Llamas, Gloria
Albuminuria is an indicator of cardiovascular risk and renal damage in hypertensive individuals. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control and prevents development of new-onset-albuminuria. A significant number of patients, however, develop albuminuria despite chronic RAS blockade, and the physiopathological mechanisms are underexplored. Urinary exosomes reflect pathological changes taking place in the kidney. The objective of this work was to examine exosomal protein alterations in hypertensive patients with albuminuria in the presence of chronic RAS suppression, to find novel clues underlying its development. Patients were followed-up for three years and were classified as: a) patients with persistent normoalbuminuria; b) patients developing de novo albuminuria; and c) patients with maintained albuminuria. Exosomal protein alterations between groups were identified by isobaric tag quantitation (iTRAQ). Confirmation was approached by target analysis (SRM). In total, 487 proteins were identified with high confidence. Specifically, 48 proteins showed an altered pattern in response to hypertension and/or albuminuria. Out of them, 21 proteins interact together in three main functional clusters: glycosaminoglycan degradation, coagulation and complement system, and oxidative stress. The identified proteins constitute potential targets for drug development and may help to define therapeutic strategies to evade albuminuria progression in hypertensive patients chronically treated.
Repisalud
Publication Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Martín-Lorenzo, Marta
  • Santiago-Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera, Martha
  • Calvo, Eva
  • Vazquez, Jesus
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope, Luis M
  • Barderas, Maria G
  • Alvarez-Llamas, Gloria
BACKGROUND AND AIMS: The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. METHODS: Eighty-one subjects (30-50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients' cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. RESULTS: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. CONCLUSIONS: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
Repisalud
Publication Artículo científico (JournalArticle)

NOMO-1 gene is deleted in early-onset colorectal cancer

  • Perea, José
  • García, Juan Luis
  • Pérez, Jessica
  • Rueda, Daniel
  • Arriba, María
  • Rodríguez, Yolanda
  • Urioste, Miguel
  • González-Sarmiento, Rogelio
To characterize clinical features of a recurrent alteration in 16p13.12-p13.11 in Colorectal Cancer (CRC), mainly in Early-onset subgroup (EOCRC), and to assess the status of NOMO1, a gene located in that region, we analyzed differential clinicopathological, familial and molecular features of CRC subsets with and without alterations in the 16p13.12-p13.11, in global and EOCRC groups. We confirmed the region by fluorescence in-situ hybridization, and Quantitative Real-Time PCR analyzed the status of NOMO1 in different age-of-onset and Microsatellite Instability (MSI)-status CRC subsets. Both age-of-onset subsets were subsequently extended to further confirm NOMO1 gene changes. 16p13.12-p13.11 alterations were observed in 23.3% of CRCs, and was detected more frequently in EOCRC (33.3%) than in late-onset CRC (16.3%). The group with deletion in 16p showed a higher frequency of females and left-colon locations; a better prognosis; and higher Chromosomal Instability. Within the primary EOCRC population, 34 out of 34 of tumours showed a homozygous deletion in NOMO1, while in the late-onset population only 2 of the 17 tumours (11.7%) showed it. In the extended group, we found 61 out of 75 EOCRC patients (81.3%) with homozygous deletion and 7 patients (9.3%) with heterozygous deletion of NOMO1; moreover, in the new 50 late-onset patients, the proportions of deletions decreased. Microsatellite-Stable (MSS) EOCRC showed a very high proportion of homozygous loss of NOMO1 (54 of 59 cases, 91.5%), while the deletion was observed in only 7 out of 16 MSI cases. Deletion of NOMO1 is a molecular marker predominantly associated with EOCRC, particularly MSS subtypes.